Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6720061 | 0.90 | NR3C2 (0.36) | PTGS2EPAS1 | |
| SCHEMBL6721402 | 0.89 | PTGS2 (0.40) | PTGS2CA12CA1CA2CA9 | |
| SCHEMBL6728553 | 0.88 | PTGS2 (0.37) | PTGS2MAPK14CSNK1DMAPK9MAPK10 | |
| SCHEMBL6721948 | 0.88 | PTGS2 (0.48) | PTGS2MAPK14CSNK1DMAPK9MAPK10 | |
| SCHEMBL6723710 | 0.87 | PTGS2 (0.45) | PTGS2MAPK14CSNK1DMAPK9MAPK10 | |
| SCHEMBL6729612 | 0.87 | PTGS2 (0.39) | PTGS2MAPK14CSNK1DMAPK9MAPK10 | |
| SCHEMBL6722731 | 0.87 | PTGS2 (0.42) | PTGS2MAPK14CSNK1DMAPK9MAPK10 | |
| SCHEMBL6726100 | 0.87 | PTGS2 (0.35) | PTGS2EPAS1CA1CA2 | |
| SCHEMBL6722738 | 0.87 | PTGS2 (0.35) | PTGS2EPAS1CA1CA2 | |
| SCHEMBL6719438 | 0.86 | PTGS2 (0.52) | PTGS2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885EPAS1 232/4885MAPK14 2499/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885EPAS1 281/4885MAPK14 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.